Pfizer Stock Price, News & Analysis

For XTANDI (enzalutamide): New post hoc analyses of long-term overall survival data, including the ARCHES five-year follow-up OS analysis in metastatic hormone-sensitive prostate cancer patients. The ENZAMET trial will present eight-year data comparing enzalutamide vs non-steroidal anti-androgen.

For PADCEV (enfortumab vedotin): Two analyses from the phase 3 EV-302 study in previously untreated locally advanced or metastatic urothelial carcinoma, featuring an exploratory analysis of responders and long-term subgroup analysis.

The presentations emphasize Astellas' focus on long-term overall survival data and clinical outcomes that matter to patients in advanced prostate and bladder cancers.

Pfizer reported solid Q1 2025 financial results with revenues of $13.7 billion, showing an 8% decrease from Q1 2024. The company achieved Adjusted Diluted EPS of $0.92, marking a 12% increase year-over-year.

Key highlights include:

• On track to exceed $4.5 billion in net cost savings by end of 2025
• Additional expected savings of $1.2 billion through 2027
• R&D reorganization to deliver $500 million in savings by 2026
• Manufacturing optimization to save $1.5 billion by 2027

The company reaffirmed its 2025 guidance with expected revenues of $61.0 to $64.0 billion and Adjusted Diluted EPS of $2.80 to $3.00. Notable product performance included growth in Vyndaqel family (+33%) and Comirnaty (+62%), while Paxlovid saw a 75% decline. The company maintained strong capital allocation, including $2.4 billion in cash dividends to shareholders.

Pfizer (NYSE: PFE) announced breakthrough results from its Phase 3 CREST trial for sasanlimab, an investigational PD-1 inhibitor, combined with BCG therapy for bladder cancer treatment. The study demonstrated a 32% reduction in disease-related events risk compared to standard BCG treatment alone.

The trial met its primary endpoint with statistically significant improvement in event-free survival (EFS). The probability of being event-free at 36 months was 82.1% with the combination therapy versus 74.8% with BCG alone. For patients with CIS who achieved complete response, the probability of maintaining response at 36 months was 91.7% with combination therapy compared to 67.7% with BCG alone.

This represents the first potential treatment advancement for BCG-naïve, high-risk non-muscle invasive bladder cancer in over 30 years. The results are particularly significant as bladder cancer is the ninth most common cancer worldwide, with NMIBC representing approximately 75% of cases. The safety profile aligned with known BCG and PD-1 inhibitor characteristics.

Guardant Health (Nasdaq: GH) has announced a strategic collaboration with Pfizer (NYSE: PFE) to advance cancer therapy development using the Guardant Infinity™ smart liquid biopsy platform. The multi-year global partnership will:

• Implement Guardant's liquid biopsy tests in Pfizer's global clinical studies
• Assess circulating tumor DNA (ctDNA) as a surrogate endpoint for therapy response monitoring
• Evaluate blood-based epigenomic analyses

The agreement includes access to Guardant's liquid biopsy tests in China for Pfizer's global clinical trials with Chinese cohorts, building on Guardant's existing partnership with Adicon Holdings announced in July 2022.

Pfizer (NYSE: PFE) has announced its second-quarter 2025 dividend declaration. The company's board of directors has approved a quarterly cash dividend of $0.43 per share, which will be paid on June 13, 2025, to shareholders of record as of May 9, 2025. This marks Pfizer's 346th consecutive quarterly dividend payment, highlighting the company's long-standing commitment to shareholder returns.

Pfizer will present significant oncology research at the ASCO 2025 Annual Meeting, featuring over 60 abstracts including 15 oral presentations. Two late-breaking presentations will showcase: primary analysis of BREAKWATER study investigating BRAFTOVI combination therapy in colorectal cancer, and VERITAC-2 study results for vepdegestrant in breast cancer.

Key highlights include five-year survival data for XTANDI in prostate cancer, first combination data for ELREXFIO in multiple myeloma, and novel antibody-drug conjugates (ADCs) research. The company will present Phase 1 data on two investigational ADCs - sigvotatug vedotin for lung and head/neck cancers, and PDL1V for head/neck cancers, both in combination with pembrolizumab.

The presentations support Pfizer's goal of delivering eight breakthrough cancer medicines by 2030, with nine new pivotal Phase 3 trials planned for 2025.

Pfizer (PFE) announced that the CDC's Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for RSV vaccines to include adults aged 50-59 at increased risk of RSV-associated lower respiratory tract disease (LRTD). This expansion specifically includes ABRYSVO®, which received FDA approval in October 2024 for preventing RSV-associated LRTD in at-risk adults aged 18-59.

According to CDC data, approximately 15,000-20,000 RSV-associated hospitalizations occur annually in U.S. adults aged 50-59. The highest risk affects those with underlying conditions such as obesity, cardiovascular disease, diabetes, COPD, asthma, and other chronic or immunocompromising conditions. ABRYSVO currently holds the broadest indication among RSV vaccines, covering older adults, at-risk adults 18 and older, and pregnant women.

Pfizer (NYSE: PFE) has announced the discontinuation of danuglipron, its oral GLP-1 receptor agonist being developed for chronic weight management. While dose-optimization studies of once-daily formulations met key pharmacokinetic objectives, the decision came after a participant experienced potential drug-induced liver injury, which resolved after discontinuing the treatment.

The studies involved over 1,400 participants, with liver enzyme elevations generally aligned with approved agents in the same class. Despite this setback, Pfizer remains committed to advancing treatments for cardiovascular and metabolic diseases, including obesity, through their oral GIPR antagonist candidate and other early-stage obesity programs.

Pfizer (NYSE: PFE) has announced its virtual 2025 Annual Meeting of Shareholders, scheduled for April 24, 2025, at 9:00 a.m. EDT. Shareholders can access the meeting through https://meetnow.global/PFE2025, with login available from 8:45 a.m. EDT.

Participants will need a control number from their proxy card, voting instruction form, or notice to ask questions and vote during the meeting. Questions can be submitted in advance until 5:00 p.m. EDT on April 22. While most shareholders can vote during the meeting, some beneficial owners may need to obtain a legal proxy and pre-register.

The meeting will also be available in listen-only mode without a control number, and a replay will be accessible for up to one year at https://investors.pfizer.com/Investors/Events--Presentations. The virtual format ensures shareholders have comparable rights and opportunities as an in-person meeting.